STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3607 by analyst upside · 2026-08-12
MRK
Merck & Company, Inc.
Healthcare · Market Cap $322B · P/E 105.2x
ANALYST PRICE TARGET
+4.9%
implied upside to consensus target
Current Price $130.42
Consensus Target $136.85
Bull Target $155.0
Bear Target $105.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
14
Hold
7
Sell
1
52-Week Low $77.58
52-Week High $135.05
YTD Return +24.3%
FUNDAMENTALS
Market Cap $322B
P/E Ratio (TTM) 105.2x
Forward P/E 13.7x
EPS (TTM) $1.24
PEG Ratio 12.53
Dividend Yield 2.60%
Revenue (TTM) $66.6B
Profit Margin 4.8%
52-WEEK RANGE
52-Week Low $77.58
52-Week High $135.05
Current Price $130.42
Bear Target $105.0
Bull Target $155.0
● Now $130.42 ● Target $136.85
TRADING DATA
Avg Volume 10.2M
YTD Return +24.3%
Analyst Count 26
Consensus Buy
Upside to Target +4.9%
Last Updated 2026-08-12

ANALYST SUMMARY

Merck & Company, Inc. (MRK) is currently trading at $130.42 with a Wall Street consensus price target of $136.85, implying potential upside of 4.9% over the next 12 months. 26 analysts currently cover MRK, with a consensus rating of Buy - 69% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $155.0, while the most cautious has a target of $105.0.

MRK operates in the Healthcare sector with a market capitalisation of $322B. The stock is up 24.3% year-to-date and is currently trading near the upper end of its 52-week range of $77.58 – $135.05.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MRK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo - Reiterated
Overweight → Overweight 2026-05-01 Building track record
UBS - Reiterated
Buy → Buy 2026-04-13 33% win rate (6 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-04-06 43% win rate (7 calls)
RBC Capital reit
Outperform → Outperform 2026-03-30 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-03-20 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-03-12 Building track record
RBC Capital ● Initiated
Outperform 2026-02-25 Building track record
Barclays ● Initiated
Overweight 2026-02-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →